(NASDAQ: ONC) Beone Medicines's forecast annual revenue growth rate of 20.5% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Beone Medicines's revenue in 2025 is $4,175,868,000.On average, 4 Wall Street analysts forecast ONC's revenue for 2025 to be $7,210,107,111,537, with the lowest ONC revenue forecast at $7,100,333,101,834, and the highest ONC revenue forecast at $7,280,658,576,385. On average, 4 Wall Street analysts forecast ONC's revenue for 2026 to be $8,715,725,188,950, with the lowest ONC revenue forecast at $8,261,994,018,825, and the highest ONC revenue forecast at $8,920,848,573,702.
In 2027, ONC is forecast to generate $10,261,125,732,341 in revenue, with the lowest revenue forecast at $9,004,626,245,536 and the highest revenue forecast at $11,157,445,782,569.